FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293849> ?p ?o ?g. }

• W4286293849 endingPage "4070" @default.
• W4286293849 startingPage "4070" @default.
• W4286293849 abstract "4070 Background: TOPAZ-1 (NCT03875235) is a randomized, double-blind, global, Phase 3 study evaluating the efficacy and safety of durvalumab (D) in combination with (+) gemcitabine and cisplatin (GC) as first-line treatment for patients (pts) with advanced biliary tract cancer (BTC). 1 D + GC significantly improved overall survival (OS) versus placebo (PBO) + GC and represents a new treatment option. Methods: A pre-planned secondary objective of TOPAZ-1 was to assess pt-reported outcomes (PROs) for pts receiving D + GC versus PBO + GC. Pts with BTC were randomized 1:1 to D (1500 mg) or PBO, + G (1000 mg/m 2 ) and C (25 mg/m 2 ), for up to 8 cycles, followed by D or PBO monotherapy until disease progression, unacceptable toxicity, or other discontinuation criteria were met. PROs were assessed with the European Organisation for Research and Treatment of Cancer 30-item Quality of Life (QoL) Questionnaire, EORTC QLQ-C30 (C30), and the BTC 21-item module, EORTC QLQ-BIL21 (BIL21). Time to deterioration (TTD) was the primary assessment of PROs; defined as the time from randomization to the date of the first pre-specified, clinically meaningful deterioration (e.g. disease progression). The PRO analysis set included all pts from the full analysis set who completed a questionnaire. Results: Compliance rates for PROs were high at baseline (>81%) and remained high (majority >70% over 28 cycles) for both treatment groups. Baseline scores were comparable between treatment groups. Addition of D was well tolerated, with no significant difference in TTD in D + GC versus PBO + GC for pt-reported symptoms or functioning using either C30 or BIL21 (Table), or Global Health Status/QoL (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.69–1.12; p=0.279). Conclusions: Addition of D to GC improved OS (Oh D-Y, et al. J Clin Oncol 2022;40(suppl 4). Abs 378) and was well tolerated with no difference in TTD of QoL for pts, supporting D + GC as a new treatment option for pts with BTC. Clinical trial information: NCT03875235. [Table: see text]" @default.
• W4286293849 created "2022-07-21" @default.
• W4286293849 creator A5014548230 @default.
• W4286293849 creator A5016033095 @default.
• W4286293849 creator A5023344582 @default.
• W4286293849 creator A5026812828 @default.
• W4286293849 creator A5031674948 @default.
• W4286293849 creator A5059766169 @default.
• W4286293849 creator A5065070005 @default.
• W4286293849 creator A5067929425 @default.
• W4286293849 creator A5072308451 @default.
• W4286293849 creator A5073763820 @default.
• W4286293849 creator A5076696174 @default.
• W4286293849 creator A5079645039 @default.
• W4286293849 creator A5082631947 @default.
• W4286293849 creator A5084399437 @default.
• W4286293849 creator A5085012371 @default.
• W4286293849 creator A5087493812 @default.
• W4286293849 date "2022-06-01" @default.
• W4286293849 modified "2023-10-18" @default.
• W4286293849 title "Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer." @default.
• W4286293849 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4070" @default.
• W4286293849 hasPublicationYear "2022" @default.
• W4286293849 type Work @default.
• W4286293849 citedByCount "7" @default.
• W4286293849 countsByYear W42862938492022 @default.
• W4286293849 countsByYear W42862938492023 @default.
• W4286293849 crossrefType "journal-article" @default.
• W4286293849 hasAuthorship W4286293849A5014548230 @default.
• W4286293849 hasAuthorship W4286293849A5016033095 @default.
• W4286293849 hasAuthorship W4286293849A5023344582 @default.
• W4286293849 hasAuthorship W4286293849A5026812828 @default.
• W4286293849 hasAuthorship W4286293849A5031674948 @default.
• W4286293849 hasAuthorship W4286293849A5059766169 @default.
• W4286293849 hasAuthorship W4286293849A5065070005 @default.
• W4286293849 hasAuthorship W4286293849A5067929425 @default.
• W4286293849 hasAuthorship W4286293849A5072308451 @default.
• W4286293849 hasAuthorship W4286293849A5073763820 @default.
• W4286293849 hasAuthorship W4286293849A5076696174 @default.
• W4286293849 hasAuthorship W4286293849A5079645039 @default.
• W4286293849 hasAuthorship W4286293849A5082631947 @default.
• W4286293849 hasAuthorship W4286293849A5084399437 @default.
• W4286293849 hasAuthorship W4286293849A5085012371 @default.
• W4286293849 hasAuthorship W4286293849A5087493812 @default.
• W4286293849 hasConcept C121608353 @default.
• W4286293849 hasConcept C126322002 @default.
• W4286293849 hasConcept C141071460 @default.
• W4286293849 hasConcept C142724271 @default.
• W4286293849 hasConcept C143998085 @default.
• W4286293849 hasConcept C159110408 @default.
• W4286293849 hasConcept C203092338 @default.
• W4286293849 hasConcept C204243189 @default.
• W4286293849 hasConcept C204787440 @default.
• W4286293849 hasConcept C27081682 @default.
• W4286293849 hasConcept C2776694085 @default.
• W4286293849 hasConcept C2777701055 @default.
• W4286293849 hasConcept C2777742743 @default.
• W4286293849 hasConcept C2778239845 @default.
• W4286293849 hasConcept C2778715236 @default.
• W4286293849 hasConcept C2779951463 @default.
• W4286293849 hasConcept C2780030458 @default.
• W4286293849 hasConcept C2780258809 @default.
• W4286293849 hasConcept C3017919176 @default.
• W4286293849 hasConcept C535046627 @default.
• W4286293849 hasConcept C71924100 @default.
• W4286293849 hasConceptScore W4286293849C121608353 @default.
• W4286293849 hasConceptScore W4286293849C126322002 @default.
• W4286293849 hasConceptScore W4286293849C141071460 @default.
• W4286293849 hasConceptScore W4286293849C142724271 @default.
• W4286293849 hasConceptScore W4286293849C143998085 @default.
• W4286293849 hasConceptScore W4286293849C159110408 @default.
• W4286293849 hasConceptScore W4286293849C203092338 @default.
• W4286293849 hasConceptScore W4286293849C204243189 @default.
• W4286293849 hasConceptScore W4286293849C204787440 @default.
• W4286293849 hasConceptScore W4286293849C27081682 @default.
• W4286293849 hasConceptScore W4286293849C2776694085 @default.
• W4286293849 hasConceptScore W4286293849C2777701055 @default.
• W4286293849 hasConceptScore W4286293849C2777742743 @default.
• W4286293849 hasConceptScore W4286293849C2778239845 @default.
• W4286293849 hasConceptScore W4286293849C2778715236 @default.
• W4286293849 hasConceptScore W4286293849C2779951463 @default.
• W4286293849 hasConceptScore W4286293849C2780030458 @default.
• W4286293849 hasConceptScore W4286293849C2780258809 @default.
• W4286293849 hasConceptScore W4286293849C3017919176 @default.
• W4286293849 hasConceptScore W4286293849C535046627 @default.
• W4286293849 hasConceptScore W4286293849C71924100 @default.
• W4286293849 hasIssue "16_suppl" @default.
• W4286293849 hasLocation W42862938491 @default.
• W4286293849 hasOpenAccess W4286293849 @default.
• W4286293849 hasPrimaryLocation W42862938491 @default.
• W4286293849 hasRelatedWork W2018086491 @default.
• W4286293849 hasRelatedWork W2043917781 @default.
• W4286293849 hasRelatedWork W2897311709 @default.
• W4286293849 hasRelatedWork W3038714164 @default.
• W4286293849 hasRelatedWork W3088708979 @default.
• W4286293849 hasRelatedWork W4240059981 @default.
• W4286293849 hasRelatedWork W4248275212 @default.
• W4286293849 hasRelatedWork W4281630496 @default.

• next